Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile CSF1R positive
Therapy Cabozantinib + Pembrolizumab
Indication/Tumor Type head and neck squamous cell carcinoma
Response Type predicted - sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CSF1R positive head and neck squamous cell carcinoma predicted - sensitive Cabozantinib + Pembrolizumab Phase II Actionable In a Phase II trial, Cometriq (Cabometyx, cabozantinib) and Keytruda (pemrolizumab) combination therapy was safe and resulted in a median progression-free survival of 12.8 mo and median overall survival (mOS) of 27.7 mo in patients with recurrent or metastatic head and neck squamous cell carcinoma, higher baseline density of CSF1R-positive cells correlated with improved OS (HR 6.87, p=0.040), with mOS not reached in high and 17.8 mo in low CSF1R-positive patients (PMID: 39167623; NCT03468218). 39167623
PubMed Id Reference Title Details
(39167623) Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker Analysis. Full reference...